ArticleAdvanced functional materials2025
Engineering Novel DNA Nanoarchitectures for Targeted Drug Delivery and Aptamer mediated Apoptosis in Cancer Therapeutics.
Article in Advanced functional materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Programmable DNA Assemblies Reconstitute Supramolecular Protein Function.bioRxiv : the preprint server for biology · 2026Article
- Retention-Based, Dissociation-Sensitive Pre-Screening of Aptamers Using a Centrifugal Microspin Filter.Biosensors · 2026Article
- Review
- CEMs-SELEX: DNAzyme-powered de novo biomarker discovery and noninvasive cancer diagnosis.Science advances · 2026Article
- Thermo-Sensitive Polymeric Networks for Next-Generation Wound Management: A Review.AAPS PharmSciTech · 2026Review
- Advances in ligand-targeted nanodelivery systems for leukemia therapy: from single- to dual-ligand strategies.Journal of translational medicine · 2026Review
- DNA Nanostructure-Templated Multivalency Enables Broad-Spectrum Virus Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- From Selection to Use: Aptamers as Targeting Reagents in Hematology.Biomedicines · 2026Review
- DNA Origami-Templated Aptamer Chiral Structures Realize Cellular Enantioselectivity.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Sequence optimization of a DNA aptamer inhibiting COVID-19 infection guided by analysis of secondary structure distribution.Computational and structural biotechnology journal · 2026Article
- DNA Nanostructure Self-Assembly in an Aqueous Ionic Liquid Solution with Enhanced Stability and Target Binding Affinity.Journal of the American Chemical Society · 2025Article
- Mesoporous silica nanoparticle-based nanomedicine: Preparation, functional modification, and theranostic applications.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
The specific and potent delivery of anticancer drugs to targeted cancer stem cells (CSCs) remains a critical need to maximize on-target, on-tumor effects while minimizing on-target, off-tumor toxicities. Herein, we present our Designer DNA Architecture (DDA)-templated Drug Conjugates (DDA-DCs) customized to deliver daunorubicin (Dau) specifically and potently to a subset of CSCs: acute myeloid leukemia (AML) leukemic stem cells (LSCs) that often maintain minimal residual disease (MRD) and cause relapse. Our DDA-DCs targeted LSCs via CD117- and CD123-binding aptamers: aptamers that when used alone disrupted the MAP Kinase and Apoptosis signaling pathways, leading to a 40% reduction in cell viability over 72 hours. These aptamers, when loaded with dsDNA-intercalating Dau and docked to DDA platforms, exhibited potent and selective cytotoxicity against CD117
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.